Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of SBRT Combined With Osimertinib Compared With Osimertinib Alone for Stage IV Non-small Cell Lung Cancer

NCT05583409 is registered in ClinicalTrials.gov with Li Zhang as lead sponsor.

NCT NCT05583409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of SBRT Combined With Osimertinib Compared With Osimertinib Alone for Stage IV Non-small Cell Lung Cancer
Lead sponsor
Li Zhang
Phase
Not applicable
Overall status
Unknown status
Start date
January 1, 2023
Completion date
December 30, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv non-small cell lung cancer